bioRxivCancer BiologyPreprint
Comparison of Tug-of-War Models Assuming Moran versus Branching Process Population Dynamics
Abstract
Mutations arising during cancer evolution are typically categorized as either drivers or passengers, depending on whether they increase the cell fitness. Recently, McFarland et al. introduced the Tug-of-War model for the joint effect of rare advantageous drivers and frequent but deleterious passengers. We examine this model under two common but distinct frameworks, the Moran model and the branching process. We show that frequently used statistics are similar between a version of the Moran model and the branching process conditioned on the final cell count, under different selection scenarios. We infer the selection coefficients for three breast cancer samples, resulting in good fits of the shape of their Site Frequency Spectra. All fitted values for the selective disadvantage of passenger mutations are nonzero, supporting the view that they exert deleterious selection during tumorigenesis that driver mutations must compensate.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Moran Process Version of the Tug-of-War Model: Complex Behavior Revealed by Mathematical Analysis and Simulation Studies
M. Kimmel, A. Bobrowski, … E. Ratajczyk·bioRxiv·Oct 20, 2021
- A tug-of-war between driver and passenger mutations in cancer and other adaptive processes
Christopher Dennis McFarland, Leonid A Mirny, Kirill S Korolev·bioRxiv·Feb 26, 2014
- On measuring selection in cancer from subclonal mutation frequencies
I. Bozic, C. Paterson, B. Waclaw·bioRxiv·Jan 24, 2019
- Reply: Neutral tumor evolution?
Timon Heide, Luis Zapata, … Andrea Sottoriva·bioRxiv·May 10, 2018
- Passenger mutations can accelerate tumor suppressor gene inactivation in cancer evolution
D. Wodarz, A. Newell, N. Komarova·bioRxiv·Oct 13, 2017
- Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer